Effects of Spironolactone Treatment on an Experimental Model of Chronic Aortic Valve Regurgitation
|
Adnane Zendaoui, Dominic Lachance, Élise Roussel, Jacques Couet, Marie Arsenault Groupe de Recherche sur les Valvulopathies, Centre de Recherche de l’Institut universitaire de Cardiologie et pneumologie de Québec, Université Laval, Québec, Canada |
|
|
Background and aim of the study: Aortic regurgitation (AR) is a disease for which there is currently no effective medical treatment. It has been shown previously in an experimental model of AR that the renin-angiotensin-aldosterone system (RAAS) plays a major role, and that medications blocking the RAAS are effective to protect against left ventricular (LV) hypertrophy and also help to maintain a normal systolic function. The role of aldosterone receptor blockers in this disease has never been evaluated. Thus, the effects were studied of the aldosterone receptor blocking agent spironolactone in a model of chronic AR in rats. |
with severe AR, compared to sham-operated and untreated AR animals. |
| Effects of Spironolactone Treatment on an Experimental Model of Chronic Aortic Valve Regurgitation | |
Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.
Purchase this Article
Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.
Website by CHP Design, London